Obesity increases free thyroxine proportionally to nonesterified fatty acid concentrations in adult neutered female cats

D C Ferguson, Z Caffall and M Hoenig

Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602, USA

(Requests for offprints should be addressed to M Hoenig; Email: mhoenig@uga.edu)

(D C Ferguson is now at Department of Veterinary Biosciences, The University of Illinois at Urbana-Champaign, Urbana, Illinois 61802, USA)

Abstract

The obese cat is a model for the study of the progression toward type 2 diabetes. In this study, the impact of obesity on the hypothalamic–pituitary–thyroid axis was examined in 21 domestic shorthair cats before and after the development of obesity, which significantly increased body mass index (BMI), % body fat (BF), and girth ($P < 0.0001$ for all). Serum total thyroxine (TT₄), tri-iodothyronine, free T₄ (FT₄) by direct dialysis, nonesterified fatty acids (NEFA), and leptin were measured, and FT₄ fraction (FFT₄) was calculated. Serum thyrotropin (TSH) concentrations were measured in nine animals by validating a heterologous canine TSH assay with recombinant feline TSH as a standard. FT₄, FFT₄, NEFAs, and leptin were significantly higher in obese cats. FT₄ had the strongest positive correlation with obesity indices BF, BMI,

girth, NEFA, and leptin. Fatty acids oleate and palmitate were shown to inhibit T₄ binding to pooled cat serum *in vitro*, suggesting the possibility that this mechanism was also relevant *in vivo*. Serum TT₄ and TSH did not rise significantly. The implications for thyroid hormone (TH) action are not yet clear, but fatty acids have been proposed to inhibit the cellular uptake of TH and/or pituitary TH receptor binding, leading to TH resistance. Increased leptin may also alter sensitivity to negative feedback of TH. In conclusion, feline obesity is associated with a significant increase in FT₄ within the normal range; future investigation into the cellular thyroid status will be necessary to establish cause and effect in this obesity model.

Journal of Endocrinology (2007) **194**, 267–273

Introduction

Cats are one of the few model species of human type 2 diabetes in which the progression towards the diabetic state can be studied longitudinally. They are the only non-primate species to develop β -cell deposits of the hallmark β -cell protein of human type 2 diabetes mellitus, amyloid (Hoenig *et al.* 2000). Thyroid hormones (THs) are involved in the regulation of metabolism, and regulate resting metabolic rate, thermogenesis, and lipolysis (Oppenheimer *et al.* 1991, Silva 1995). However, studies of thyroid function in obese people have produced inconsistent results. Obesity has resulted in either no changes in thyroid-stimulating hormone (TSH) or TH concentrations in the hands of some investigators (Glass & Kushner 1996, Roti *et al.* 2000), a moderate rise in total and free tri-iodothyronine (T₃) and TSH serum concentrations (Bray *et al.* 1976, Matzen *et al.* 1989, Stichel *et al.* 2000, Reinehr & Andler 2002), or an increase in total thyroxine (TT₄) and TSH (Iacobellis *et al.* 2005). A study of over 6000 human patients established a positive correlation between body mass index (BMI) and serum TSH concentrations (Nyren *et al.* 2006). Some studies are confounded by an underlying incidence of overt or subclinical hypothyroidism, as reflected by the observation of a low free T₄ (FT₄) and high

TSH concentration (Knudsen *et al.* 2005), or low total T₃ (TT₃) and TT₄ with increased TSH and thyroid volume, suggesting a primary disruption of TH synthesis (Sari *et al.* 2003). A progressive increase in serum T₃ concentration and a concomitant fall in reverse T₃ concentration have also been observed (Davidson & Chopra 1979).

Clinical studies of spontaneous obesity in dogs have resulted in similar discrepancies: in a case study of 31 obese canine patients, 58% had results consistent with overt or equivocal primary hypothyroidism (Martin *et al.* 2006). In another study, serum TT₄ and T₃ concentrations were higher but only T₃ decreased with food restriction (Daminet *et al.* 2003).

It has been suggested that the cause of the increased serum TH concentrations together with an increase in TSH might be caused by hypothalamic–pituitary–TH resistance (Edupuganti *et al.* 1997). Supporting this hypothesis is the observation that T₃ receptors are decreased in obesity and the negative feedback of circulating THs on TSH is decreased (Burman *et al.* 1980). Several studies have tried to establish a link between TH and leptin on energy expenditure; however, others have shown that the action of leptin was not dependent on the presence of TH (Vettor 2005).

Despite the variety of prior studies, none have ascertained the mechanism of the increase in free and/or total TH

concentrations in obesity. Most studies in man have been in spontaneously obese patients and interpretation has been complicated by the uncertainty of the underlying incidence of subclinical hypothyroidism. Cats are not prone to the development of spontaneous adult onset hypothyroidism to the extent of man or dog, having only a small incidence of congenital disease (Tobias & Labato 2001). We have previously shown that obese cats have decreased heat production and changes in fat metabolism (Hoenig *et al.* 2007a,b), raising the possibility that alterations in fat mass may impact hypothalamic–pituitary–thyroid axis function as well as calorogenesis. Therefore, in this study, we sought to study lean euthyroid cats before and again after the development of stable obesity to identify potential effects on the hypothalamic–pituitary–thyroid axis.

Materials and Methods

Animals

Twenty-one adult (aged 1–2 years) neutered purpose-bred female cats (Sinclair, Columbia, MO, USA and Harlan Sprague–Dawley, Madison, WI, USA) were used. All cats were maintained at the University of Georgia College of Veterinary Medicine Animal Care Facility, using standard colony conditions. Cats were housed separately in cages and were provided unlimited access to water. Animal studies were approved by the University of Georgia Animal Care and Use Committee and conducted in accordance with the guidelines established by the Animal Welfare Act and the National Institutes of Health. It was determined that the cats were healthy on the basis of results of physical examination and clinical laboratory tests. All cats were used to being handled daily. All cats were fed a commercially available diet (Iams Ocean Fish and Rice, Dayton, OH, USA) once daily and food intake was recorded at each feeding. Their weight was monitored weekly. BMI and % fat mass were measured as described (Hoenig *et al.* 2003) at the beginning of the study and after the cats had gained ~40% of fat mass. At both time points, blood was drawn, allowed to clot, and serum was collected after centrifugation at 500 g for 10 min. The serum was stored at –20 °C until assayed.

TH and NEFA assays

Serum TT₄ and TT₃ were measured by previously described and validated procedures using in-house RIAs with commercially prepared antibodies (Endocrine Sciences, Tarzana, CA, USA) as described previously (Peterson *et al.* 1983, Ferguson & Peterson 1992). Free T₄ (FT₄) concentrations were measured by direct dialysis using the Nichols Institute (San Juan Capistrano, CA, USA) kit. Leptin was measured using the Linco multi-species leptin ELISA as validated for cats (Hoenig *et al.* 2003). Nonesterified fatty acids (NEFAs) were measured using an enzymatic test kit (Wako Diagnostic, Richmond, PA, USA). In the cats, the FT₄ fraction expressed

as a percentage was calculated as: % FT₄ = FT₄ concentration (pmol/l)/TT₄ concentration (nmol/l) × 10.

Although each animal served as its own control, for purposes of comparison, the normal ranges for hormonal analytes as determined by values 2 s.d. above and below the mean in 30 lean cats in our research colony were: TT₄ (12–29 nmol/l), TT₃ (0.06–1.1 nmol/l), FT₄ (15–40 pmol/l), and FT₄ fraction (FFT₄) (0.05–0.23%). The values demonstrated a parametric distribution.

Serum TSH immunoassay

The commercial canine TSH immunoassay (Immulite Canine TSH, Diagnostic Products Corporation Inc., (DPC) Los Angeles, CA, USA) was standardized for feline TSH using a standard curve of purified recombinant feline TSH prepared as described by Rayalam *et al.* (2006a,b). In brief, the protein concentration of the purified recombinant feline TSH (rfTSH) standard was determined by bicinchoninic acid protein assay using bovine TSH as a protein standard. Purity of the recombinant hormone was established by densitometric analysis of a silver-stained PAGE. For rfTSH preparations in which this gravimetric analysis was performed in parallel with measurement in this commercial canine TSH assay, rfTSH was detected with 34.0 ± 6.2% (mean ± s.d.) efficiency. We noted that recombinant canine TSH prepared, expressed, and purified with the same techniques was detected with 73.6% efficiency. The rfTSH standards diluted in the serum ‘blank’ provided in the commercial assay showed linearity with the provided canine TSH standards (*R* = 0.999) with an intercept indistinguishable from zero. Using this standardized assay, serum TSH concentrations were determined in nine animals during the lean and obese state. To facilitate comparison with other studies using this canine TSH assay to measure feline TSH, the values directly derived from the canine standard curve (i.e. uncorrected for efficiency of detection of rfTSH) were reported. For comparison, one laboratory has reported immunoreactive TSH in normal cats as measured in the DPC canine TSH assay to be 0.03–0.11 ng/ml with a detection limit of 0.03 ng/ml and a median of 0.05 ng/ml (Moore *et al.* 2004).

FT₄ fraction by tracer equilibrium dialysis: effect of added NEFAs

To directly evaluate the effect of specific NEFAs on serum binding of T₄, a tracer dialysis procedure was used as described for dog serum (Ferguson & Peterson 1992). In brief, customized Plexiglas chambers with dialysand and dialysate chamber volumes of 1 ml were used. High specific activity ¹²⁵I-T₄ was purchased from Perkin–Elmer (Wellesley, MA, USA) and added to a 5% solution of BSA and pre-dialyzed against 0.15 M NaH₂PO₄, pH 7.4, overnight to remove iodide. Pooled normal cat serum was used for these *in vitro* studies and was assayed to have 0.159 mEq/l non-esterified fatty acids. Stock solutions of sodium oleate and sodium palmitate (Sigma Chemical Co.) were prepared in 1% BSA solution at 300 mEq/l and, by dilution, to 100, 60, 30,

and 10 mEq/l. Sera with added NEFAs were prepared by a 1:100 dilution of the stock, resulting in final concentrations of 0.159, 0.259, 0.459, 0.759, 1.159, and 3.159 mEq/l, and allowed to pre-incubate 30 min at room temperature. Ten microliters of the pre-dialyzed tracer (0.1–0.2 μ Ci) were then added to the serum and incubated for 30 min at room temperature. One milliliter of serum and of the dialysis buffer was added to each side of the chamber, sealed, and allowed to dialyze for 16–24 h. The dialysate buffer was then subject to magnesium precipitation to remove residual iodide in the dialysate and FT₄ fraction calculated as described previously (Ferguson & Peterson 1992).

Statistical analysis

All data were analyzed using computer software (Prism software, GraphPad Software Inc, San Diego, CA, USA). The data are expressed as means $\pm$ s.d. unless otherwise stated. The significance of differences of means was evaluated by paired *t*-test. Values of $P < 0.05$ were considered significant.

Results

Body weight, fat mass, girth, and BMI were significantly higher between the lean and obese state (Table 1). Leptin increased from 327 ± 17 to 482 ± 48 (pmol/l; $P < 0.004$), as did NEFAs. They were 0.33 ± 0.04 mEq/l in the lean state and 0.49 ± 0.05 mEq/l in the obese state ($P < 0.002$).

TT₄, TT₃, and FT₄ concentrations, and % FFT₄ are shown in Fig. 1A–D. Although TT₄ trended to be higher in obese than lean cats ($P < 0.08$), this was not significant. TT₃ also did not change significantly with an increase in fat mass; however, FT₄ was significantly higher in obese than lean cats ($P < 0.0001$), as was FFT₄ ($P < 0.004$). FT₄ correlated positively and significantly with all indices of obesity (body weight, $P < 0.002$; % body fat (BF), $P < 0.0001$, Fig. 2A; girth, $P < 0.0001$; and BMI, $P < 0.02$). FT₄ also correlated positively with NEFA ($P < 0.025$, Fig. 2B) and leptin ($P < 0.04$). TT₄ correlated positively and significantly with all indices of obesity (body weight, $P < 0.001$; % fat, $P < 0.02$; girth, $P < 0.003$; and BMI, $P < 0.03$), as well as with leptin ($P < 0.002$) but not with NEFA. TT₃ correlated positively with weight ($P < 0.004$), girth ($P < 0.013$), and BMI ($P < 0.04$). FFT₄ correlated significantly and linearly with NEFA concentration (Fig. 2C; $P < 0.002$).

Mean ($\pm$ s.d.) TSH concentration (ng/ml) measured in nine cats during the lean state was 0.038 ± 0.016 ng/ml, and in the obese state was 0.048 ± 0.024 ng/ml, an insignificant rise. All samples were above the lower limit of detection of 0.01 ng/ml against the canine TSH standard.

When specific NEFAs were examined for effects of displacing tracer T₄ from pooled cat serum, oleate and palmitate increased FFT₄ at a concentration above 1 mEq/l (Fig. 3). This *in vitro* effect appears to confirm a direct inhibitory effect of common circulating NEFAs on T₄ binding to cat serum proteins, an effect seen at NEFA concentrations observed in obese cats, and one which would account in significant part for the elevations in FT₄ concentrations by direct dialysis seen in obese patients.

Discussion

The observation of an increase in FT₄ in cats developing obesity is similar to those reported in a recent study of obese women. Serum concentrations of TSH, T₄, T₃, and FT₄ were observed to be elevated (Kozłowska & Rosołowska-Huszcz 2004). This study did not see the FFT₄ fall during weight loss and attributed it to potentially increased non-esterified fatty acids, although they were not measured, nor was FT₄ measured by a dialysis procedure. However, while multiple studies have demonstrated a positive correlation between TSH and BMI, they generally have noted a negative association between BMI and FT₄ concentrations, albeit with changes within normal range. It should be noted that non-dialysis techniques were used to estimate FT₄ concentration (Knudsen *et al.* 2005).

Our studies of developing obesity in cats suggest that a primary alteration in thyroid function is an alteration of FFT₄ induced by the increase in NEFAs, and that this effect can be mimicked in pooled cat serum by the addition of the exogenous NEFAs oleic or palmitic acid. It is possible that a larger sample size might have demonstrated a significant increase in TT₄ and TT₃, and it is notable that both correlated significantly with the obesity indices of weight, girth, and BMI, and TT₄ also correlated with BF and leptin. The lack of significant changes in TT₃ or TT₄ is inconsistent with studies in man, which have generally shown an increase in T₃ production and rT₃ degradation rates, with no change in net T₄ production or degradation, suggesting an increase in the Type I 5'-deiodinase (D1) enzyme activity (Roti *et al.* 2000). Studies in the dog

Table 1 Body weight (kg), body fat (%), girth (m), and body mass index (kg/m²) in 21 neutered female adult cats before (lean) and after becoming obese (obese). Variances are s.d.

	Body weight (kg)	Body fat (%)	Girth (m)	Body mass index (kg/m ²)
Lean	4.2 $\pm$ 0.5	23.6 $\pm$ 6.2	0.37 $\pm$ 0.04	44.3 $\pm$ 6.2
Obese	5.0 $\pm$ 0.7 [†]	36.8 $\pm$ 5.9 [†]	0.43 $\pm$ 0.01 [*]	54.7 $\pm$ 7.1 [†]

Significance when compared in paired analysis with same parameter in the lean state * $P < 0.004$, [†] $P < 0.0001$.

showed an increase in T₃, but no change in reverse T₃ concentrations (Daminet *et al.* 2003). Conversely, the Type II 5′-deiodinase (D2) was shown to be decreased in white adipose tissue of obese human patients (Nauman *et al.* 1990).

Establishing cause and effect for the observed changes is difficult with this study alone. However, it should be noted that the tightest correlations to FT₄ were with % BF and between FFT₄ and NEFAs (Fig. 2). Furthermore, the changes in the calculated FFT₄ *in vivo* are made more plausible by the *in vitro* evidence that NEFAs can increase FFT₄ at concentration ranges achieved during obesity.

TSH is a very sensitive marker of altered thyroid status in man with exponential increases or decreases with linear changes in FT₄ concentrations. If the change in plasma NEFA concentration was the initial and sole effect, one would predict that FT₄ would be transiently increased, TSH would suppress transiently, and then TT₄ would fall, until FT₄ normalized. However, to explain the results, it is necessary to postulate that there is a concomitant change in the sensitivity of the hypothalamus and/or pituitary to negative feedback. In cats progressing to the obese state, FT₄ remained elevated, TT₄ was unchanged (with a trend toward elevation, not depression), and TSH did not change, and in no case in which it was measured, was it undetectable as is observed in spontaneous hyperthyroidism. Measurement of serum TSH in additional cats might have uncovered a significant change in TSH, but TSH measurements were not initially planned because recombinant feline TSH was not yet available to standardize the canine assay.

We propose that obesity induces a relative state of TH resistance, either caused by the effect of leptin or by the effect of increased NEFA concentrations, or both. The diagnostic criterion for TH resistance is an elevated FT₄ with a normal or elevated TSH concentration, and we believe that these observations are consistent with this criterion (Brucker-Davis *et al.* 1995, Larsen & Davies 2003). Most often when TSH and TH concentrations are elevated in obese human subjects, they are still within the normal range (Reinehr & Andler 2002, Michalaki *et al.* 2006, Nyren *et al.* 2006).

Accurate measurement of TSH is critical to the accurate interpretation of the physiological significance of the increased FT₄ concentrations in obesity. This is the first report of the use of a commercially available canine TSH assay to measure serum feline TSH with documentation of detection efficiency of a feline TSH standard of known gravimetric purity. It is apparent that detection of feline TSH by the Immulite canine TSH assay is less complete (46%) than that observed with recombinant canine TSH. We would note that the predicted normal range for this small sample of lean

Figure 1 Serum concentrations of total T₄ (A), total T₃ (B), direct dialysis free T₄ (FT₄; C), and calculated free fraction of T₄ (FFT₄; D) in 21 cats before (lean) and after becoming obese (obese). Error bars are S.D. Values with the same superscript letter differ significantly. Significance when compared in paired analysis with same parameter in the lean state: ***P* < 0.0001, **P* < 0.004.

Figure 2 (A) Correlation between FT₄ (pM) and body fat (%) in 21 neutered female adult cats before and after becoming obese ($r^2 = 0.38$, $P < 0.0001$). (B) Correlation between FT₄ (pM) and nonesterified fatty acids (mEq/l) in 21 neutered female adult cats before and after becoming obese ($r^2 = 0.11$, $P < 0.03$). (C) Correlation between FFT₄ (%) and nonesterified fatty acids (mEq/l) in 21 neutered female adult cats before and after becoming obese ($r^2 = 0.22$, $P < 0.03$).

cats would predict a normal range with 95% confidence limits for TSH of 0.01–0.21 ng/ml, much closer to those observed in the normal dog (<0.5 ng/ml) or human (0.02–0.32 ng/ml, assuming 0.08 ng/microunit bioactivity (Nyrmes

Figure 3 Effect of added oleic and palmitic acids on the displacement of ¹²⁵I-T₄ from pooled cat serum as reflected by the free T₄ fraction (%) determined by equilibrium dialysis *in vitro*. Points represent the average three replicate dialyses per concentration.

et al. 2006). Higher concentrations would be more consistent with the concentration range observed for the IC₅₀s for bovine TSH displacement of ¹²⁵I-bovine TSH from the feline TSH receptor (0.19 nmol/l or 5.5 ng/ml; Nguyen *et al.* 2002) and for recombinant feline TSH stimulation of adenylate cyclase in cells expressing the human TSH receptor (10.7 vs 4.9 ng/ml for bovine TSH; Rayalam *et al.* (2006a,b).

The current study is the first to identify a relationship between the rise in FT₄ associated with obesity being linked to the rise in NEFA. There may be several reasons that the elevation of FT₄ had not previously been identified. First with the exception of one study of dogs (Daminet *et al.* 2003), non-dialysis analog procedures for determining FT₄ have generally been employed. Analog FT₄ assays are not as likely to distinguish the effect of low-affinity inhibitors of serum TH binding such as NEFAs (Nelson *et al.* 2005). In studies of healthy euthyroid dogs, a good correlation between dialysis and analog FT₄ immunoassays has been observed (Schachter *et al.* 2004, Martin *et al.* 2006). However, this correlation tends to degrade when sick animals are evaluated suggesting that these assays may be incapable of discerning the effects of weak circulating weak inhibitors of serum TH binding (Schachter *et al.* 2004).

Secondly, the current study evaluated the same cat as it progressed from the lean to the obese state. It is also worth noting that, for most of the prior studies, FT₄ and, when it was measured, TSH generally remained within the normal range. Given intersubject variation, this pathophysiological mechanism may have been obscured when lean and obese groups were distinct populations.

Thirdly, cats are a species that have very low concentrations of specific serum thyroid-hormone-binding proteins such as thyroxine-binding globulin (TBG), which dominate serum binding of T₄ in primates (Refetoff *et al.* 1970). As such, changes in NEFA concentrations may have a greater tendency to impact TH binding in serum. Given the close similarity of the composition of serum thyroid-hormone-binding proteins in

dogs and cats, it is interesting to compare the results in cats with a study of separate groups of lean and obese laboratory beagles (Daminet *et al.* 2003). The obese dogs had significantly elevated serum TT_4 and T_3 concentrations, but neither TSH nor FT_4 , measured by equilibrium dialysis, was increased. The investigators suggest that the T_4 increase in obesity could be the result of an increase in the serum concentration of thyroid-hormone-binding proteins, specifically TBG. However, they also show that the maximum serum T_4 response following TSH administration was not different. From this, one would conclude that the thyroid functional reserve is unchanged in obesity, and the results are more suggestive of a change in hypothalamic–pituitary set point than that of a change in binding protein capacity (Daminet *et al.* 2003).

Aside from the hypothesis of TH resistance associated with increased NEFA concentrations, the increase in FT_4 observed in the cats during the obese phase of this study could be the result of other factors changing the hypothalamic–pituitary set point for negative feedback. Some studies have demonstrated an increase in free TH as well as TSH concentrations in humans (Duntas *et al.* 1991). TSH increases in another study were shown to be proportional to BMI (Nyrenes *et al.* 2006). In support of this theory is the fact that in obesity, nuclear T_3 receptors are decreased in number (Burman *et al.* 1980) and, presumably, the negative feedback between the TSH and the peripheral THs and TSH secretion, mediated by the $TR\beta$ nuclear thyroid receptor of the hypothalamus and pituitary, is decreased. As demonstrated in the rat, some compounds may inhibit binding of TH to $TR\beta$ without affecting $TR\alpha$, resulting in tissue hyperthyroidism where the latter receptor subtype exists (Zoeller *et al.* 2005). Our study of cats showed no significant increase in TSH concentration with obesity. This does not preclude the presence of an altered set point for negative feedback as a normal TSH concentration is inappropriately high in the face of the elevation of FT_4 concentration. In the obese dog, the elevated baseline T_4 but identical maximal response of T_4 to TSH also suggests that there was a change in hypothalamic–pituitary set point, albeit with a normal baseline TSH concentration (Daminet *et al.* 2003). It has been suggested that measurement of the serum response of TSH to administered TRH would be useful to ascertain whether pituitary sensitivity is altered in obesity. However, at least in one study of obese patients, the response of TSH to i.v. TRH was not altered (Duntas *et al.* 1991). Future studies will be necessary to address this question in the cat.

Leading theories suggest that leptin and the adrenergic neurotransmitters are key regulators of the hypothalamic–pituitary–thyroid axis. When human subjects were sampled every 10 min for leptin and TSH concentrations, there was a linear relationship between the 24-h leptin and TSH, with a significantly higher 24-h rate in obese but a lower rate in fasted patients. Indeed, leptin has been shown to also correlate with thyroid volume (Ghizzoni *et al.* 2001). However, leptin and TSH concentrations both correlate with the degree of obesity, obscuring whether there is a cause–effect relationship. Reduced dopamine 2 (D2) receptors in the brain have been observed in

obesity (Pinkney *et al.* 1998, Kok *et al.* 2005), and production of TSH is also regulated by transmitters and hormones, which regulate body weight and satiety, such as the neurotransmitters neuropeptide Y, α -melanocyte-stimulating hormone, and the agouti-related peptide, which interact with hypothalamic TRH neurons (Fekete *et al.* 2000, 2001, 2002, Guo *et al.* 2004).

In summary, the development of obesity in the cat is associated with a significant increase in FT_4 within the normal reference range, a change that correlated with the increase in plasma NEFA concentrations. We propose that the effect of obesity on FT_4 is primary as FT_4 and FFT_4 were most tightly correlated with BF and plasma NEFA concentrations. However, the set point for negative feedback on TSH secretion must also be altered as TT_4 and TSH concentrations remained unchanged, and TT_4 did not fall inversely with the rise in FT_4 . Furthermore, we were able to demonstrate that the *in vitro* addition of NEFAs led to a significant increase of the FT_4 fraction. It is difficult to ascertain whether the cats developed a change in their tissue thyroid status upon the development of obesity.

Further investigation into the cellular thyroid status will be necessary to establish cause and effect in this animal model of obesity. It will require the measurement of markers of TH action in peripheral tissue such as muscle or adipose tissue to evaluate whether there might be tissue-specific changes in the TH's action resulting from the increased serum FT_4 concentration.

Funding

This study was supported in part through the University of Georgia Veterinary Medical Alumni Fund. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References

- Bray GA, Fisher DA & Chopra IJ 1976 Relation of thyroid hormones to body-weight. *Lancet* **1** 1206–1208.
- Brucker-Davis F, Skarulis MC, Grace MB, Benichou J, Hauser P, Wiggs E & Weintraub BD 1995 Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. *Annals of Internal Medicine* **123** 572–583.
- Burman KD, Latham KR, Djuh YY, Smallridge RC, Tseng YC, Lukes YG, Maunder R & Wartofsky L 1980 Solubilized nuclear thyroid hormone receptors in circulating human mononuclear cells. *Journal of Clinical Endocrinology and Metabolism* **51** 106–116.
- Daminet S, Jeusette I, Duchateau L, Diez M, Van de Maele I & De Rick A 2003 Evaluation of thyroid function in obese dogs and in dogs undergoing a weight loss protocol. *Journal of Veterinary Medicine. A. Physiology, Pathology, Clinical Medicine* **50** 213–218.
- Davidson MB & Chopra IJ 1979 Effect of carbohydrate and noncarbohydrate sources of calories on plasma 3,5,3'-triiodothyronine concentrations in man. *Journal of Clinical Endocrinology and Metabolism* **48** 577–581.
- Duntas L, Hauner H, Rosenthal J & Pfeiffer EF 1991 Thyrotropin releasing hormone (TRH) immunoreactivity and thyroid function in obesity. *International Journal of Obesity* **15** 83–87.
- Edupaganti S, Svec F, Bao W, Srinivasan SR & Berenson GS 1997 Thyroid function in children with different lipoprotein profiles: observations in a biracial (black/white) population – the Bogalusa Heart Study. *American Journal of the Medical Sciences* **313** 80–84.

- Fekete C, Legradi G, Mihaly E, Huang QH, Tatro JB, Rand WM, Emerson CH & Lechan RM 2000 Alpha-melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. *Journal of Neuroscience* **20** 1550–1558.
- Fekete C, Kelly J, Mihaly E, Sarkar S, Rand WM, Legradi G, Emerson CH & Lechan RM 2001 Neuropeptide Y has a central inhibitory action on the hypothalamic–pituitary–thyroid axis. *Endocrinology* **142** 2606–2613.
- Fekete C, Sarkar S, Rand WM, Harney JW, Emerson CH, Bianco AC & Lechan RM 2002 Agouti-related protein (AGRP) has a central inhibitory action on the hypothalamic–pituitary–thyroid (HPT) axis; comparisons between the effect of AGRP and neuropeptide Y on energy homeostasis and the HPT axis. *Endocrinology* **143** 3846–3853.
- Ferguson DC & Peterson ME 1992 Serum free and total iodothyronine concentrations in dogs with hyperadrenocorticism. *American Journal of Veterinary Research* **53** 1636–1640.
- Glizzoni L, Mastorakos G, Zivieri M, Furlini M, Solazzi A, Vottero A & Bernasconi S 2001 Interactions of leptin and thyrotropin 24-hour secretory profiles in short normal children. *Journal of Clinical Endocrinology and Metabolism* **86** 2065–2072.
- Glass A & Kushner J 1996 Obesity, nutrition, and the thyroid. *Endocrinology* **6** 392–403.
- Guo F, Bakal K, Minokoshi Y & Hollenberg AN 2004 Leptin signaling targets the thyrotropin-releasing hormone gene promoter *in vivo*. *Endocrinology* **145** 2221–2227.
- Hoenig M, Hall G, Ferguson D, Jordan J, Henson M, Johnson K & O'Brien TD 2000 A feline model of experimentally induced islet amyloidosis. *American Journal of Pathology* **157** 2143–2150.
- Hoenig M, Wilkins C, Holson JC & Ferguson DC 2003 Effects of obesity on lipid profiles in neutered male and female cats. *American Journal of Veterinary Research* **64** 299–303.
- Hoenig M, Thomaseth K, Waldron M & Ferguson DC 2007a Fatty acid turnover, substrate oxidation, and heat production in lean and obese cats during the euglycemic hyperinsulinemic clamp. *Domestic Animal Endocrinology* **32** 329–338.
- Hoenig M, Thomaseth K, Waldron M & Ferguson DC 2007b Insulin sensitivity, fat distribution, and adipocytokine response to different diets in lean and obese cats before and after weight loss. *American Journal of Physiology. Regulatory, Integrative and Comparative Physiology* **292** R227–R234.
- Iacobellis G, Ribaldo MC, Zappaterreno A, Iannucci CV & Leonetti F 2005 Relationship of thyroid function with body mass index, leptin, insulin sensitivity and adiponectin in euthyroid obese women. *Clinical Endocrinology* **62** 487–491.
- Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L & Jorgensen T 2005 Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. *Journal of Clinical Endocrinology and Metabolism* **90** 4019–4024.
- Kok P, Roelfsema F, Langendonk JG, Frolich M, Burggraaf J, Meinders AE & Pijl H 2005 High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. *Journal of Clinical Endocrinology and Metabolism* **90** 4659–4663.
- Kozłowska L & Rosolowska-Huszcz D 2004 Leptin, thyrotropin, and thyroid hormones in obese/overweight women before and after two levels of energy deficit. *Endocrine* **24** 147–153.
- Larsen PR & Davies TF 2003 Hypothyroidism and thyroiditis. In *Williams Textbook of Endocrinology*, edn 10, pp 441–442. Eds PR Larsen, HM Kronenberg, SM Melmed & KS Polonsky. Philadelphia: Saunders.
- Martin LJ, Siliart B, Dumon HJ & Nguyen PG 2006 Hormonal disturbances associated with obesity in dogs. *Journal of Animal Physiology and Animal Nutrition* **90** 355–360.
- Matzen LE, Kvetny J & Pedersen KK 1989 TSH, thyroid hormones and nuclear-binding of T₃ in mononuclear blood cells from obese and non-obese women. *Scandinavian Journal of Clinical and Laboratory Investigation* **49** 249–253.
- Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE & Kyriazopoulou VE 2006 Thyroid function in humans with morbid obesity. *Thyroid* **16** 73–78.
- Moore KL, Syme H & Groves E 2004 Use of endogenous thyroid stimulating hormone measurement to diagnose hyperthyroidism in cats with chronic renal failure. *British Small Animal Veterinary Association Scientific Proceedings* **521** (abst. 32).
- Nauman A, Nauman J, Sypniewska G, Fiedorowicz K & Bielecki K 1990 Regulation of triiodothyronine levels in fatty tissue in obese patients. *Wiadomości Lekarskie* **43** 427–432.
- Nelson JC, Wang R, Asher DT & Wilcox RB 2005 Underestimates and overestimates of total thyroxine concentrations caused by unwanted thyroxine-binding protein effects. *Thyroid* **15** 12–15.
- Nguyen LQ, Arseven OK, Gerber H, Stein BS, Jameson JL & Kopp P 2002 Cloning of the cat TSH receptor and evidence against an autoimmune etiology of feline hyperthyroidism. *Endocrinology* **143** 395–402.
- Nyrmes A, Jorde R & Sundsfjord J 2006 Serum TSH is positively associated with BMI. *International Journal of Obesity* **30** 100–105.
- Oppenheimer JH, Schwartz HL, Lane JT & Thompson MP 1991 Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. *Journal of Clinical Investigation* **87** 125–132.
- Peterson ME, Kintzer PP, Cavanagh PG, Fox PR, Ferguson DC, Johnson GF & Becker DV 1983 Feline hyperthyroidism: pretreatment clinical and laboratory evaluation of 131 cases. *Journal of American Veterinary Medical Association* **183** 103–110.
- Pinkney JH, Goodrick SJ, Katz J, Johnson AB, Lightman SL, Coppack SW & Mohamed-Ali V 1998 Leptin and the pituitary–thyroid axis: a comparative study in lean, obese, hypothyroid and hyperthyroid subjects. *Clinical Endocrinology* **49** 583–588.
- Rayalam S, Eizenstat LD, Hoenig M & Ferguson DC 2006a Cloning and sequencing of feline thyrotropin (fTSH): heterodimeric and yoked constructs. *Domestic Animal Endocrinology* **30** 203–217.
- Rayalam S, Eizenstat LD, Davis RR, Hoenig M & Ferguson DC 2006b Expression and purification of feline thyrotropin (fTSH): immunological detection and bioactivity of heterodimeric and yoked glycoproteins. *Domestic Animal Endocrinology* **30** 185–202.
- Refetoff S, Robin NI & Fang VS 1970 Parameters of thyroid function in serum of 16 selected vertebrate species: a study of PBI, serum T₄, free T₄, and the pattern of T₄ and T₃ binding to serum proteins. *Endocrinology* **86** 793–805.
- Reinehr T & Andler W 2002 Thyroid hormones before and after weight loss in obesity. *Archives of Disease in Childhood* **87** 320–323.
- Roti E, Minelli R & Salvi M 2000 Thyroid hormone metabolism in obesity. *International Journal of Obesity and Related Metabolic Disorders* **24** (Suppl 2) S113–S115.
- Sari R, Balci MK, Altunbas H & Karayalcin U 2003 The effect of body weight and weight loss on thyroid volume and function in obese women. *Clinical Endocrinology* **59** 258–262.
- Schachter S, Nelson RW, Scott-Moncrieff C, Ferguson DC, Montgomery T, Feldman EC, Neal L & Kass PH 2004 Comparison of serum-free thyroxine concentrations determined by standard equilibrium dialysis, modified equilibrium dialysis, and 5 radioimmunoassays in dogs. *Journal of Veterinary Internal Medicine* **18** 259–264.
- Silva JE 1995 Thyroid hormone control of thermogenesis and energy balance. *Thyroid* **5** 481–492.
- Stichel H, l'Allemand D & Gruters A 2000 Thyroid function and obesity in children and adolescents. *Hormone Research* **54** 14–19.
- Tobias S & Labato MA 2001 Identifying and managing feline congenital hypothyroidism. *Veterinary Medicine* **96** 719–726.
- Vettor R 2005 The metabolic actions of thyroid hormone and leptin: a mandatory interplay or not? *Diabetologia* **48** 621–623.
- Zoeller RT, Bansal R & Parris C 2005 Bisphenol-A, an environmental contaminant that acts as a thyroid hormone receptor antagonist *in vitro*, increases serum thyroxine, and alters RC3/neurogranin expression in the developing rat brain. *Endocrinology* **146** 607–612.

Received in final form 19 April 2007

Accepted 9 May 2007

Made available online as an Accepted Preprint
15 May 2007